Sign up to save your podcasts
Or
Share From Big Pharma to the Biotech C-Suite and Beyond: Industry and Career Insights from Dr. June Almenoff (Ep. 6 of The Pharmcast)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
From Big Pharma to the Biotech C-Suite and Beyond: Industry and Career Insights from Dr. June Almenoff (Ep. 6 of The Pharmcast)
This week on The Pharmcast, we talk with Dr. June Almenoff, former President, Chief Medical Officer and Board Member of a biotech, which was recently acquired in 2014 by Forest Laboratories for $1.2 billion.
Almenoff helped the company successfully progress its Irritable Bowel Syndrome drug from Phase 2 through the FDA submission, which the FDA approved in 2013.
Everyone talks about learning from failure, but this week, we learn from success. Join us as we sit down with Dr. Almenoff to talk about her story and lessons she learned along the way.
View all episodes
By YourEncore, Inc.This week on The Pharmcast, we talk with Dr. June Almenoff, former President, Chief Medical Officer and Board Member of a biotech, which was recently acquired in 2014 by Forest Laboratories for $1.2 billion.
Almenoff helped the company successfully progress its Irritable Bowel Syndrome drug from Phase 2 through the FDA submission, which the FDA approved in 2013.
Everyone talks about learning from failure, but this week, we learn from success. Join us as we sit down with Dr. Almenoff to talk about her story and lessons she learned along the way.